ClinicalTrials.gg
Active, not recruitingNCT05464381Updated Dec 10, 2025

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)

A Phase 3 interventional study of allo-APZ2-OTS and Placebo in Epidermolysis Bullosa, sponsored by RHEACELL GmbH & Co. KG. Active, not recruiting at 16 sites in 12 countries. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by RHEACELL GmbH & Co. KG · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
91
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Epidermolysis Bullosa with a site in France — 1 open to participants now, 2 under way, 1 of them phase 3. Epidermolysis Bullosa · France.

Enrollment
4th of 11
91 · median 16
Started
2023
with 2 others
Phase 3
6 of 14
none open now
Registered
12th of 14
by date
Lead sponsor
2 of 14
RHEACELL GmbH & Co. KG

Among the 14 studies in Epidermolysis Bullosa with a site in France, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 in phase 3, and was the 12th registered.

Epidermolysis Bullosa

86 studies on the registry are indexed under Epidermolysis Bullosa; 18 are open to participants now.

Browse Epidermolysis Bullosa studies →

Open to participants now

1 of the 14 studies in Epidermolysis Bullosa with a site in France is open now. Recruiting first, the newest first:

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Epidermolysis Bullosa with a site in France, or all of them as a file.
02

Study summary

The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo. An additional baseline-controlled open-label arm will be included to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with JEB and to RDEB subjects \< 1 year.

03

Conditions studied

  • Epidermolysis Bullosa

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects with a diagnosis of RDEB or JEB confirmed by genetic testing or by a skin with immunofluorescence mapping (IFM). A minimal body weight of at least 5 kg is required;
  2. Subject is eligible to participate in this clinical trial based on general health condition;
  3. Subject with a target wound meeting the following criteria: 5-50 cm2, and \< 9 months, no signs of acute infection;
  4. Patient/legal representative understands the nature of the procedure and provide written /assent prior to any clinical trial procedure;
  5. Women of must have a negative urine pregnancy test at Visit 1. Women of childbearing potential, male participants, and their partner must be willing to use highly effective methods during the course of the entire clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Signs and/or a history of skin precancerous and cancerous lesions at screening or any current tumor diseases, including squamous cell carcinoma and basal cell carcinoma;
  2. Known chronic lung disease;
  3. laboratory values for coagulation and at screening;
  4. Thromboembolic events of any grade in medical history;
  5. Immunoreactions of any grade in medical history;
  6. Any known allergies to components of the IP or premedication;
  7. Patient/legal representative anticipated to be unwilling or unable to comply with the requirements of the protocol;
  8. Pregnant or lactating women;
  9. Current or previous (within 30 days of screening) treatment with another IP, or participation and/or under follow-up in another interventional clinical trial;
  10. Previous participation in this clinical trial (except for screening failures);
  11. Clinically significant or unstable concurrent disease or other clinical like an uncontrolled or poorly controlled mental health condition of the subject and/or his/her legal representative that could impact on patient's safety or interfere with study compliance such as inability to attend scheduled study visits;
  12. Employees of the sponsor, or employees or relatives of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Verum

    Drug: allo-APZ2-OTS

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Drugallo-APZ2-OTS

    Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with complete target wound closure

    Proportion of subjects with complete healing of target wound, determined by the investigator, as compared to baseline

    Time frame: 6 months

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Aug 2025, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2022
First posted
Jul 19, 2022
StartActual
Jun 13, 2023
Primary completionActual
Aug 29, 2025
CompletionEst.
Jan 2027
Last update
Dec 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05464381
Lead sponsor
RHEACELL GmbH & Co. KG
Responsible party
Sponsor
First posted
Jul 19, 2022
Start date
Jun 13, 2023
Primary completion
Aug 29, 2025
Completion
Jan 2027 (estimated)
Last update
Dec 10, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion